Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease

by Nathaniel Kleytman, Jiapeng Ruan, Audrey Ruan, Bailin Zhang, Vagishwari Murugesan, Haiqun Lin, Lilu Guo, Katherine Klinger, Pramod K. Mistry
Published 2021-12-01

Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data

by Tatiana Raskovalova, Patrick B. Deegan, Ruby Yang, Elena Pavlova, Jérome Stirnemann, José Labarère, Ari Zimran, Pramod K. Mistry, Marc Berger
Published 2017-04-01

Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease

by Gillian C. Goobie, Sandra M. Sirrs, John Yee, John C. English, Celine Bergeron, Roland Nador, John R. Swiston, Pramod K. Mistry, Wendy Paquin, Robert D. Levy
Published 2019-01-01

The Role of ARF6 in Biliary Atresia.

by Mylarappa Ningappa, Juhoon So, Joseph Glessner, Chethan Ashokkumar, Sarangarajan Ranganathan, Jun Min, Brandon W Higgs, Qing Sun, Kimberly Haberman, Lori Schmitt, Silvia Vilarinho, Pramod K Mistry, Gerard Vockley, Anil Dhawan, George K Gittes, Hakon Hakonarson, Ronald Jaffe, Shankar Subramaniam, Donghun Shin, Rakesh Sindhi
Published 2015-01-01